Italian study on depressive disorders (Studio Italiano malattia depressiva, or STIMA-D): A nationwide snapshot of the status of treatment for major depression

Pharmacopsychiatry

Volumn 47, Issue 3, 2014, Pages 105-110

  Aguglia, E ^a   Biggio, G ^b   Signorelli, M S ^a   Mencacci, C ^c  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

^c FATEBENEFRATELLI HOSPITAL   (Italy)

Author keywords

antidepressants; major depression; relapse; side effects

Indexed keywords

CITALOPRAM; DULOXETINE; ESCITALOPRAM; PAROXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE; ANTIDEPRESSANT AGENT; SEROTONIN RECEPTOR AFFECTING AGENT;

ADULT; AGED; ANORGASMIA; ANXIETY DISORDER; ARTICLE; ASTHENIA; DEPRESSION; DISEASE ASSOCIATION; FAMILY HISTORY; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INCREASED APPETITE; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEDICATION THERAPY MANAGEMENT; MONOTHERAPY; MOOD DISORDER; MULTICENTER STUDY; PATIENT CARE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; SOMNOLENCE; TREATMENT OUTCOME; TREATMENT RESPONSE; ADOLESCENT; AGE; CLINICAL TRIAL; DEPRESSIVE DISORDER, MAJOR; ITALY; MIDDLE AGED; PHYSICIAN; PSYCHOLOGY; QUALITY OF LIFE; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; ITALY; MALE; MIDDLE AGED; PHYSICIANS; QUALITY OF LIFE; SEROTONIN AGENTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84901256397     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0034-1375628     Document Type: Article

References (27)

1. The World Health Organization The global burden of disease. 2004 update. Table A2: Burden of disease in DALYs by cause, sex and income group in WHO regions, estimates for 2004. Geneva, Switzerland WHO: 2008; http://www.who.int/ healthinfo/global-burden-disease/GBD-report-2004update-full.pdf
2. De Girolamo G., Polidori G., Morosini P. et al. La prevalenza dei disturbi mentali in Italia. Il progetto ESEMeD-WMH. Epidemiol Psichiatr Soc: 2005; 14 1 100
3. Waraich P., Goldner E. M., Somers J. M. et al. Prevalence and incidence studies of mood disorders: a systematic review of the literature. Can J Psychiatry: 2004; 49 124 138 (Pubitemid 38387422)
4. Fournier J. C., DeRubeis R. J., Hollon S. D. et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA: 2010; 303 47 53
5. Singleton N., Bumpstead R., O'Brien M. et al. Psychiatric morbidity among adults living in private households, 2000. Int Rev Psychiatry: 2003; 15 65 73 (Pubitemid 36363527)
6. Coyne J. C., Schwenk T. L., Fechner-Bates S. Nondetection of depression by primary care physicians reconsidered. Gen Hosp Psychiatry: 1995; 17 3 12
7. Tiemens B. G., Ormel J., Simon G. E. Occurrence, recognition, and outcome of psychological disorders in primary care. Am J Psychiatry: 1996; 153 636 644
8. Simon G. E., Goldberg D., Tiemens B. G. et al. Outcomes of recognized and unrecognized depression in an international primary care study. Gen Hosp Psychiatry: 1999; 21 97 105 (Pubitemid 29200430)
9. Egede L. E. Failure to recognize depression in primary care: issues and challenges. J Gen Intern Med: 2007; 22 701 703 (Pubitemid 46941197)
10. Goldberg D., Huxley P. Mental Illness in the Community: The Pathway to Psychiatric Care. London Tavistock: 1980
11. Saver B. G., Van-Nguyen V., Keppel G. et al. A qualitative study of depression in primary care: missed opportunities for diagnosis and education. J Am Board Fam Med: 2007; 20 28 35 (Pubitemid 46219397)
12. Meltzer H., Bebbington P., Brugha T. et al. The reluctance to seek treatment for neurotic disorders. J Mental Health: 2000; 9 319 327 (Pubitemid 30479114)
13. Martinotti G., Sepede G., Gambi F. et al. Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder. J Clin Psychopharmacol: 2012; 32 487 491
14. Hickie I. B., Rogers N. L. Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet: 2011; 378 621 631
15. Di Giannantonio M., Martinotti G. Anhedonia and major depression: the role of agomelatine. Eur Neuropsychopharmacol: 2012; 22 S505 S510
16. Aguglia E., Minutolo G., Signorelli M. S. et al. I bisogni non risolti della depressione maggiore. Giorn Ital Psicopat: 2011; 17 328 334
17. Biggio G. Basi neurobiologiche e farmacologiche di una innovativa terapia antidepressiva. Giorn Ital Psicopat: 2011; 17 335 340
18. Cuijpers P., Sijbrandij M., Koole S. L. et al. Adding psychotherapy to antidepressant medication in depression and anxiety disorders: a meta-analysis. World Psychiatry: 2014; 13 56 67
19. Thase M. E., Greenhouse J. B., Frank E. et al. Treatment of major depression with psychotherapy or psychotherapy-pharmacology combinations. Arch Gen Psychiatry: 1997; 54 1009 1015 (Pubitemid 27476096)
20. Angst J., Cui L., Swendsen J. et al. Major depressive disorder with subthreshold bipolarity in the National Comorbidity Survey Replication. Am J Psychiatry: 2010; 167 1194 1201
21. Fava G. A., Savron G., Grandi S. et al. Cognitive-behavioral management of drug-resistant major depressive disorder. J Clin Psychiatry: 1997; 58 278 282 (Pubitemid 27318573)
22. Mueller T. I., Leon A. C., Keller M. B. et al. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry: 1999; 156 1000 1006 (Pubitemid 29302790)
23. Andlin-Sobocki P., Wittchen H. U. Cost of affective disorders in Europe. Eur J Neurol: 2005; 12 34 38 (Pubitemid 40755601)
24. Kind P., Sorensen J. The costs of depression. Int Clin Psychopharmacol: 1993; 7 191 195 (Pubitemid 23008945)
25. Thomas C., Morris S. Cost of depression among adults in England in 2000. Br J Psychiatry: 2003; 183 514 519 (Pubitemid 37533197)
26. Stoudemire A., Frank R., Hedemark N. et al. The economic burden of depression. Gen Hosp Psychiatry: 1986; 8 387 394 (Pubitemid 17180971)
27. Gustavsson A., Svensson M., Jacobi F. et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol: 2011; 21 718 779